Purple Biotech (PPBT) Stock Gains Pre-Hour Momentum
In pre-market trading, Purple Biotech Ltd. (NASDAQ: PPBT) had a notable stock increase this morning, going up 57.08% to $5.27. The spike comes after PPBT revealed positive Phase 2 clinical research findings for CM24, its top cancer medication. Patients with pancreatic ductal adenocarcinoma (PDAC) were screened for this humanized monoclonal antibody, which targets CEACAM1. Phase […]
Purple Biotech (PPBT) Stock Gains Pre-Hour Momentum Read More »